美股异动 | BioNTech(BNTX.US)盘前跌逾1% 遭大摩下调目标价至150美元
格隆汇3月31日丨BioNTech(BNTX.US)盘前跌1.4%,报120.85美元。大摩分析师Matthew Harrison将BioNTech的目标价从216美元下调至150美元,并保持对该股的持股观望评级。BioNTech第四季度收入超过预期,但这“不是投资者关注的焦点”,因为管理层指引2023年新冠疫苗销售额约为50亿欧元,而共识预测为80亿欧元。大摩降低了对该公司新冠疫苗业务的中期收入,以考虑指引和欧盟合同的重新调整,并表示随着“新冠相关数字现在被重置”,2023年的重点可以转移到研发生产系统。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.